cause it is widely available, has a low cost and it is associated with a low number and intensity of side effects. In the present review the different methods to stimulate Ct and the cut-offs for the identification of the hyperplastic/neoplastic transformation of the C cells will be reported and discussed.
1,300 patients with nodular thyroid disease, the routine measurement of Ct allowed to identify 8 MTCs, only 2 of whom were diagnosed also by a suggestive cytology [2] . After that study, many others, for a total of more than 70,000 cases, reported the results obtained with the routine measurement of Ct, with a mean prevalence of MTC of 0.5%. Interestingly, around half of the MTCs found were micro-MTCs, confirming the importance of the routine measurement of Ct in the early diagnosis of C-cell diseases [3] . The impact on survival was clearly demonstrated in a study including 44 patients (group 1) diagnosed with MTC by the routine Ct measurement and 45 patients diagnosed by other methods (group 2). A statistically significant difference in the rate of complete remission was found between the two groups of patients (59% in group 1 and in 2.7% in group 2, p ! 0.0001), highlighting that the routine Ct measurement should always be considered in the diagnostic evaluation of thyroid nodules [4, 5] . Nevertheless, this practice remains controversial and is definitely accepted only for the screening of familial MTC. In particular, the European Consensus recommended it, whereas the American Thyroid Association guidelines do not recommend either for or against it [6, 7] . Moreover, the recent American-European-Italian joined guidelines consider that the testing of Ct may be a useful test in the initial evaluation of thyroid nodules, but do not recommend its routine use [8] .
Routine Measurement of Calcitonin: Why Not?
The major arguments against the routine measurement of Ct are reported below: (1) Costs/benefits. The prevalence of MTC is low, around 0.5% of the population with thyroid nodules. For this reason it has been argued that the routine testing of serum Ct in all patients with unselected thyroid nodules could not be cost-effective. Nevertheless, a very detailed study has recently demonstrated that this test has a cost/benefit ratio similar to those of TSH neonatal screening, and colonoscopy and mammogram screening [1] . (2) Uncertain evolution of micro-MTCs. Since around half of the tumors identified by routine Ct measurement are micro-MTCs, it has been argued that these tumors could have a highly reduced malignant potential and will never become larger and aggressive tumors. Indeed the prevalence of MTCs in unselected autopsies is roughly comparable to the Ct screening studies in the thyroid nodule population [3] .
(3) Risk of false-positive results. These are mostly due to assay interferences, such as the presence of heterophilic antibodies that can cause falsely elevated and rarely falsely reduced Ct levels. Nevertheless, these interferences are usually abolished by the use of immunometric chemiluminescent assays two-site, two-step (ICMAs), highly specific for monomeric Ct. (4) Presence of secondary C-cell hyperplasia, which can be related to: (a) thyroid diseases: autoimmunity (in 20% of cases), benign or malignant nodules; (b) other diseases: severe renal insufficiency, hyperparathyroidism, hypergastrinemia. (5) Increased basal Ct secretion during treatment with drugs, such as omeprazole, ␤ -blockers, glucocorticoids secretagogues and cigarette smoking [9, 10] . (6) Production of Ct by neuroendocrine tumors. In this context, it should be underlined that neuroendocrine tumors usually produce less Ct per gram of tissue than MTC and typically do not increase their Ct secretion in response to the stimulation testing. (7) Difficulties in the set-up of the cut-offs for both basal and stimulated Ct needed to identify the C-cell diseases. (8) Unavailability in the USA, and now also in Europe, of pentagastrin (Pg) which has been considered for several years as the best test to stimulate Ct.
The Cut-Offs for Pg Test
The Pg test has largely been used for many years to stimulate Ct. The procedure consists of the injection of 0.5 g/kg over 5 s and in the basal, +1-2, +5 and +10-15 min sampling. Several patients have been tested and many studies have been published with the aim to establish the most precise cut-offs to differentially diagnose between normal, C-cell hyperplasia (CCH) and MTC [11] [12] [13] [14] [15] . The results of these papers have been summarized in table 1 . The indication for surgery is almost widely accepted for Ct-stimulated levels 1 100 pg/ml, whereas the best treatment for cases with stimulated Ct 1 50 pg/ ml is still controversial. Interestingly, in a recent study we demonstrated that, in patients with multinodular goiter, Pg-stimulated Ct levels 1 50 pg/ml were always associated with a diffuse/nodular CCH. Moreover, in all cases the C cells displayed a neoplastic phenotype, concerning morphology, distribution and localization, indistinguishable from that found in familial MTC and thus considered as a preneoplastic lesion. According to those findings, in patients with Pg-stimulated Ct levels 1 50 pg/ml a 'prophy-lactic' surgical treatment should be considered [16] . Nevertheless, it should be highlighted that the peak value of stimulated Ct should be interpreted not only as an absolute value, but also taking into account the basal level of Ct and, more importantly, the degree of Ct increase after stimulus. Indeed, MTC has been found to be associated with a minimum percent increment of 160% [2] .
Why It Is So Difficult to Establish a Definite Cut-Off
There are some reasons to explain the difficulties in the definition of the cut-offs.
(1) Different assays in different centers. Although international guidelines recommend each center to establish its own cut-off values for basal and stimulated Ct [6, 7] , the existence of different ranges largely contributes to the difficulties in the identification of definite basal and stimulated Ct levels to differentiate between normal and C-cell diseases. (2) Lack of different children-and gender-related ranges.
Although Ct values in children are believed to be higher than in adults, American Thyroid Association (ATA) guidelines report that due to the limited data available, caution should be used in interpreting Ct values in children ! 3 years of age [10] . In a large cohort of healthy subjects we found that the normal range of serum Ct levels was wider in children ( ! 0.2-11.7 pg/ ml for female and ! 0.2-17 pg/ml for males) than in adults, without significant gender differences in the children population [18] . In adults, Ct values should be interpreted in the setting of sex-specific reference ranges, as suggested by ATA guidelines [10] , though most centers to date have a unisex threshold for Ct levels. Indeed, since men physiologically have twice as many C cells as women [18] , both basal and stimulated Ct secretion are gender-related [9] . In this context, it has been demonstrated that gender-specific Ct thresholds predict occult MTC more accurately among patients with increased basal Ct levels than unisex thresholds. In particular, the most discriminatory threshold between CCH and MTC was found to be for basal Ct of 15 pg/ml for women and 80 pg/ml for men, and for Pg-stimulated Ct of 80 pg/ml for women and 500 pg/ml for men [12] .
The Calcium Test
The unavailability of Pg in the United States and recently also in most European countries recently raised the need to standardize other methods to stimulate Ct. The calcium (Ca) test was seldom used in the 1970s and 1980s, but has been abandoned in the last 30 years ( table 2 ). There are some basic reasons for the removal of the Ca test from clinical practice: (1) different doses in different protocols: from 2 up to 15 mg/kg of elemental Ca (Ca 2+ ); (2) lack of a precise specification of the dose of Ca 2+ (to be obtained from the starting solution, i.e. from Ca gluconate of Ca chloride); (3) different times of injection: from 1 min to 4 h; (4) use of protocols including the injection of Pg and Ca on consecutive days [19] or Ca together with Pg [20] , and (5) no data available on the cutoff levels to be used for the preoperative identification of a CCH or a MTC.
Moreover, the Ca test was initially performed as a long Ca infusion, with 3.75-5 mg/kg/h for a total duration of 3-4 h. This procedure had the disadvantage of the large amount of Ca infused, usually around 1.5 g, which produced a significant and prolonged elevation of plasma Ca, rendering it not acceptable for the screening of a large number of family members [21] . In addition, discordant data were available about the potency of the test, though the majority of studies indicated that Pg had a better stimulator than Ca. In particular, Hennessy et al. [20] and Verdy et al. [22] , according to the Ca equivalents calculator on the website http://www-users.med. cornell.edu/ ϳ spon/picu/calc/cacalc.htm. As stated above, the test was abandoned for many years up until it was reevaluated in 2009 by Doyle et al. [26] , who reported data in 50 healthy subjects. They decided to use a dose of 2.5 mg/kg of elemental Ca in accord with the dose of 2-3 mg/ kg which was the most frequently used in the 1970s and 1980s ( table 2 ). The authors concluded that the Ca test is more potent and better tolerated than Pg. In particular, they found that the peak of Ct after Pg injection is around 10 pg/ml for males and 4 pg/ml for females, consistent with previous results reporting Pg-stimulated values of around 15 and 5 pg/ml, respectively [27] . On the other hand, the levels of Ct after Ca 2+ stimulation resulted in being higher, around 40 pg/ml for men and 20 pg/ml for women. To extend the results obtained in healthy subjects and to get more insight into the standardization of the Ca 2+ test, we recently published the results obtained in controls, in patients with multinodular goiter and in patients with both familial and sporadic MTC, either in persistence or in remission [28] . As far as normal controls are concerned, peak serum Ct levels after Ca infusion did not significantly differ between men and women (around 20 and 15 pg/ml, respectively). In 4 of 16 controls, both tests were carried out and similar responses between Pg and Ca 2+ were obtained in 3 patients whereas in 1 female only Ca 2+ was able to stimulate a response of Ct ( fig. 1 ), [26] who reported a higher potency of Ca 2+ with respect to Pg. In patients with MTC and nodular goiter, we found a nice correlation between the two tests, without statistically significant differences in the levels of Pg or Ca 2+ serum Ct in patients submitted to both tests. Nevertheless, serum Ct levels have been found to be higher after Ca 2+ than after Pg in several patients, indicating that studies in larger samples could reveal a higher potency of the Ca test. ROC plot analyses were used to find the basal and Ca 2+ -stimulated Ct thresholds able to differentiate between normal, CCH, and MTC, for men and women. As reported in table 3 , all patients with basal Ct levels 1 10 pg/ml were submitted to the Ca 2+ test and the levels of basal and stimulated Ct were compared with the histological findings. The results obtained showed that the Ca 2+ -stimulated Ct thresholds able to distinguish normal controls and CCH cases from patients with MTC were 184 pg/ml for females and 1,620 pg/ml for males [28] . Concerning the degree of Ct elevation after stimulus, MTC was associated with ⌬ increases ranging from 5.6 to 64.8 for females to 5.9 -92.3 for males ( table 3 ) .
Calcium Test: Procedure and Side Effects
To date, the paper by our group is the only one to report the cut-offs for Ca-stimulated Ct [28] . The Ca test was performed according to the following procedure:
Ca gluconate was administered intravenously at a dose of 25 mg/kg at 10 ml/min (this corresponds to 2.3 mg/ kg or 0.12 mEq/kg of elemental Ca). In clinical practice it is recommended to use 10% Ca gluconate: each 10-ml vial contains 950 mg monohydrate of Ca gluconate (corresponding to 88.3 mg or 4.41 mEq of elemental Ca). Thus, for a 50-kg subject the dose of Ca gluconate needed is: 25 ! 50 = 1,250 mg. The following calculation will be: 950: 10 = 1,250:x (x = 13.15 ml of 10% Ca gluconate solution). Serial measurement demonstrated that at 2 min after Ca infusion, ionized Ca levels increase by 30-35% and then progressively decrease, whereas PTH levels decrease by 50-60% and continue to decrease. 30 min after high Ca infusion, Ca levels were 5-10% higher than baseline and PTH levels were 65-70% lower than baseline.
Overall, the number, intensity and duration of side effects were significantly lower during the Ca test and all patients declared that they preferred it. Nausea and abdominal cramping were the most frequent discomforts during the Pg test and were poorly tolerated by patients. On the contrary, the feeling of warmth, which was the most frequent and often the only side effect with Ca test, was not considered unpleasant ( fig. 2 ) .
Ca is known to increase cardiac contractility and it could lead to hypertensive peaks. On the other hand, hypertension can cause bradycardia. Thus, anamnestic data related to cardiopathy or bradycardia or severe hypertension should be obtained by patients. In selected cases, the test can be done under cardiac monitoring. Nevertheless, in our hands, neither electrocardiographic changes nor heart rate variations have ever been observed. The test has also been performed without any side effects in hyperparathyroid patients [28] .
Other Tests
Scanty data are available on other tests for Ct stimulation. In a small series of 6 patients and 8 controls, the stimulus with whisky resulted in being less efficient than Pg and Ca [23] . Omeprazole has also been used to stimulate Ct at a dosage of 20 mg twice daily for 3-4 days, with blood sampling every morning [29, 30] . Although a steady and significant increase in Ct levels was achieved, omeprazole appeared to be less potent and sensitive than Pg. Thus, its use should be limited to cases where Pg or Ca 2+ cannot be performed.
Discussion
MTC is a potentially highly aggressive tumor and the diagnostic/therapeutic tools available to date are limited and not sufficiently sensitive or effective. Thus, an early diagnosis is mandatory, which can be achieved by RET genetic testing and routine Ct measurement. In particular, Ct (basal and stimulated) allows early diagnosis either pre-or post-surgery. The majority of studies have been performed using the stimulus with Pg and cut-offs for Pg-stimulated Ct are available. Unfortunately, Pg has virtually become unavailable. For this reason, in the last 2 years the Ca test, which was abandoned in the last 30 years, has been demonstrated to represent a good choice to stimulate Ct. Some data are available on the stimulation response in normal subjects and in patients with Ca gluconate doses of 25 mg/kg, corresponding to 2.3 mg/ kg of elemental Ca [26, 28] . In these studies, Ca has been found to be equivalent or superior to Pg in the stimulation of Ct for the diagnosis and follow-up of MTC. Moreover, cut-off values to differentially diagnose among CCH and MTC in either males or females have been recently reported by our group [28] . Nevertheless, to better refine the cut-off values, more series tested with the same Ca protocol are definitely needed. In conclusion, Ca is widely available, has a low cost and it has been demonstrated to have at least the same potency of Pg and should thus be used for the diagnosis and follow-up of MTC. The personal final auspice of the author is that the availability of Ca and the easiness of execution of the test could render the routine measurement of Ct more widely used.
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